Using Weighted Gene Co-Expression Network Analysis to Identify Increased MND1 Expression as a Predictor of Poor Breast Cancer Survival

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Zhu J, Wu G, Zhao Y, et al. Epidemiology, treatment and prognosis analysis of small cell breast carcinoma: a population-based study. Front Endocrinol. 2022;13:802339. doi:10.3389/fendo.2022.802339
   PubMed Web of Science ®Google Scholar
• Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–1150. doi:10.1016/S0140-6736(16)31891-8
   PubMed Web of Science ®Google Scholar
• Jung KH, Ataseven B, Verrill M, et al. Adjuvant subcutaneous trastuzumab for HER2-positive early breast cancer: subgroup analyses of safety and active medical conditions by body weight in the SafeHer phase III study. Oncologist. 2018;23(10):1137–1143. doi:10.1634/theoncologist.2018-0065
   PubMed Web of Science ®Google Scholar
• Rimawi M, Ferrero JM, de la Haba-rodriguez J, et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol. 2018;36(28):2826–2835. doi:10.1200/JCO.2017.76.7863
   PubMed Web of Science ®Google Scholar
• Sagara Y, Takada M, Ohi Y, et al. Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03. Breast Cancer Res Treat. 2018;171(3):675–683. doi:10.1007/s10549-018-4873-0
   PubMed Web of Science ®Google Scholar
• Takada M, Sugimoto M, Masuda N, et al. Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm. Breast Cancer Res Treat. 2018;172(3):611–618. doi:10.1007/s10549-018-4958-9
   PubMed Web of Science ®Google Scholar
• Tang J, Yang Q, Cui Q, et al. Weighted gene correlation network analysis identifies RSAD2, HERC5, and CCL8 as prognostic candidates for breast cancer. J Cell Physiol. 2020;235(1):394–407. doi:10.1002/jcp.28980
   PubMed Web of Science ®Google Scholar
• Guo X, Xiao H, Guo S, Dong L, Chen J. Identification of breast cancer mechanism based on weighted gene coexpression network analysis. Cancer Gene Ther. 2017;24(8):333–341. doi:10.1038/cgt.2017.23
   PubMed Web of Science ®Google Scholar
• Dezso Z, Oestreicher J, Weaver A, et al. Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells. PLoS One. 2014;9(8):e106131. doi:10.1371/journal.pone.0106131
   PubMed Web of Science ®Google Scholar
• Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–140. doi:10.1093/bioinformatics/btp616
   PubMed Web of Science ®Google Scholar
• Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11(10):R106. doi:10.1186/gb-2010-11-10-r106
   PubMed Web of Science ®Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 2008;9(1):559. doi:10.1186/1471-2105-9-559
   PubMed Web of Science ®Google Scholar
• Botia JA, Vandrovcova J, Forabosco P, et al. An additional k-means clustering step improves the biological features of WGCNA gene co-expression networks. BMC Syst Biol. 2017;11(1):47. doi:10.1186/s12918-017-0420-6
   PubMed Web of Science ®Google Scholar
• Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57. doi:10.1038/nprot.2008.211
   PubMed Web of Science ®Google Scholar
• Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11. doi:10.1186/1752-0509-8-S4-S11
   PubMed Web of Science ®Google Scholar
• Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012;19(2):197–208. doi:10.1530/ERC-11-0329
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi:10.1093/nar/gkx247
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166–180. doi:10.1593/neo.07112
   PubMed Web of Science ®Google Scholar
• Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–D963. doi:10.1093/nar/gkx1090
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.002
   PubMed Web of Science ®Google Scholar
• Modhukur V, Iljasenko T, Metsalu T, et al. MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics. 2018;10(3):277–288. doi:10.2217/epi-2017-0118
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhao N, Zhang X, et al. SurvivalMeth: a web server to investigate the effect of DNA methylation-related functional elements on prognosis. Brief Bioinform. 2021;22(3):bbaa162. doi:10.1093/bib/bbaa162
   PubMed Web of Science ®Google Scholar
• Anuraga G, Wang WJ, Phan NN, et al. Potential prognostic biomarkers of NIMA (Never in Mitosis, Gene A)-Related Kinase (NEK) family members in breast cancer. J Pers Med. 2021;11(11):1089. doi:10.3390/jpm11111089
   PubMed Web of Science ®Google Scholar
• Liu F, Wu H. Identification of prognostic biomarkers and molecular targets among JAK family in breast cancer. J Inflamm Res. 2021;14:97–114. doi:10.2147/JIR.S284889
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Subramanian A, Narayan R, Corsello SM, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171(6):1437–1452.e17. doi:10.1016/j.cell.2017.10.049
   PubMed Web of Science ®Google Scholar
• Wang CY, Chiao CC, Phan NN, et al. Gene signatures and potential therapeutic targets of amino acid metabolism in estrogen receptor-positive breast cancer. Am J Cancer Res. 2020;10(1):95–113.
   PubMed Web of Science ®Google Scholar
• Ye H, Sun M, Huang S, et al. Gene network analysis of hepatocellular carcinoma identifies modules associated with disease progression, survival, and chemo drug resistance. Int J Gen Med. 2021;14:9333–9347. doi:10.2147/IJGM.S336729
   PubMed Web of Science ®Google Scholar
• Inari H, Suganuma N, Kawachi K, et al. Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer. Breast Cancer. 2017;24(6):748–755. doi:10.1007/s12282-017-0774-z
   PubMed Web of Science ®Google Scholar
• Piri R, Ghaffari A, Azami-Aghdash S, Ali-Akbar YP, Saleh P, Naghavi-Behzad M. Ki-67/MIB-1 as a prognostic marker in cervical cancer - A systematic review with meta-analysis. Asian Pac J Cancer Prev. 2015;16(16):6997–7002. doi:10.7314/APJCP.2015.16.16.6997
   PubMedGoogle Scholar
• Li W, Zhang G, Wang HL, Wang L. Analysis of expression of cyclin E, p27kip1 and Ki67 protein in colorectal cancer tissues and its value for diagnosis, treatment and prognosis of disease. Eur Rev Med Pharmacol Sci. 2016;20(23):4874–4879.
   PubMed Web of Science ®Google Scholar
• Xiong DD, Zeng CM, Jiang L, Luo DZ, Chen G. Ki-67/MKI67 as a predictive biomarker for clinical outcome in gastric cancer patients: an updated meta-analysis and systematic review involving 53 studies and 7078 patients. J Cancer. 2019;10(22):5339–5354. doi:10.7150/jca.30074
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen ZD, et al. siRNA targeting survivin inhibits growth and induces apoptosis in human renal clear cell carcinoma 786-O cells. Pathol Res Pract. 2009;205(12):823-7. doi:10.1016/j.prp.2009.06.018.
   Google Scholar
• Jiang G, Jiang AJ, Cheng Q, Tian H, Li LT, Zheng JN. A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis. Tumour Biol. 2013;34(2):1263–1271. doi:10.1007/s13277-013-0701-7
   PubMedGoogle Scholar
• Townsley FM, Aristarkhov A, Beck S, Hershko A, Ruderman JV. Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proc Natl Acad Sci U S A. 1997;94(6):2362–2367. doi:10.1073/pnas.94.6.2362
   PubMed Web of Science ®Google Scholar
• Dastsooz H, Cereda M, Donna D, Oliviero S. A comprehensive bioinformatics analysis of UBE2C in cancers. Int J Mol Sci. 2019;20(9):2228. doi:10.3390/ijms20092228
   PubMed Web of Science ®Google Scholar
• Qin T, Huang G, Chi L, et al. Exceptionally high UBE2C expression is a unique phenomenon in basal-like type breast cancer and is regulated by BRCA1. Biomed Pharmacother. 2017;95:649–655. doi:10.1016/j.biopha.2017.08.095
   PubMed Web of Science ®Google Scholar
• Rawat A, Gopal G, Selvaluxmy G, Rajkumar T. Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole. Cell Oncol. 2013;36(6):459–467. doi:10.1007/s13402-013-0150-8
   Web of Science ®Google Scholar
• Ko E, Kim Y, Cho EY, et al. Synergistic effect of Bcl-2 and cyclin A2 on adverse recurrence-free survival in stage I non-small cell lung cancer. Ann Surg Oncol. 2013;20(3):1005–1012. doi:10.1245/s10434-012-2727-2
   PubMed Web of Science ®Google Scholar
• Bendris N, Arsic N, Lemmers B, Blanchard JM. Cyclin A2, Rho GTPases and EMT. Small GTPases. 2012;3(4):225–228. doi:10.4161/sgtp.20791
   PubMedGoogle Scholar
• Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledge-based human protein atlas. Nat Biotechnol. 2010;28(12):1248–1250. doi:10.1038/nbt1210-1248
   PubMed Web of Science ®Google Scholar
• Gao T, Han Y, Yu L, Ao S, Li Z, Ji J. CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance. PLoS One. 2014;9(3):e91771. doi:10.1371/journal.pone.0091771
   PubMed Web of Science ®Google Scholar
• Dachineni R, Ai G, Kumar DR, Sadhu SS, Tummala H, Bhat GJ. Cyclin A2 and CDK2 as novel targets of aspirin and salicylic acid: a potential role in cancer prevention. Mol Cancer Res. 2016;14(3):241–252. doi:10.1158/1541-7786.MCR-15-0360
   PubMed Web of Science ®Google Scholar
• Bublik DR, Scolz M, Triolo G, Monte M, Schneider C. Human GTSE-1 regulates p21(CIP1/WAF1) stability conferring resistance to paclitaxel treatment. J Biol Chem. 2010;285(8):5274–5281. doi:10.1074/jbc.M109.045948
   PubMed Web of Science ®Google Scholar
• Scolz M, Widlund PO, Piazza S, et al. GTSE1 is a microtubule plus-end tracking protein that regulates EB1-dependent cell migration. PLoS One. 2012;7(12):e51259. doi:10.1371/journal.pone.0051259
   PubMed Web of Science ®Google Scholar
• Utrera R, Collavin L, Lazarevic D, Delia D, Schneider C. A novel p53-inducible gene coding for a microtubule-localized protein with G2-phase-specific expression. EMBO J. 1998;17(17):5015–5025. doi:10.1093/emboj/17.17.5015
   PubMed Web of Science ®Google Scholar
• Subhash VV, Tan SH, Tan WL, et al. GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells. BMC Cancer. 2015;15(1):550. doi:10.1186/s12885-015-1550-0
   PubMed Web of Science ®Google Scholar
• Guo L, Zhang S, Zhang B, et al. Silencing GTSE-1 expression inhibits proliferation and invasion of hepatocellular carcinoma cells. Cell Biol Toxicol. 2016;32(4):263–274. doi:10.1007/s10565-016-9327-z
   PubMed Web of Science ®Google Scholar
• Lee J, Sung CO, Lee EJ, et al. Metastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the ATM gene. PLoS One. 2012;7(4):e34456. doi:10.1371/journal.pone.0034456
   PubMed Web of Science ®Google Scholar
• Neapolitan RE, Jiang X. Study of integrated heterogeneous data reveals prognostic power of gene expression for breast cancer survival. PLoS One. 2015;10(2):e0117658. doi:10.1371/journal.pone.0117658
   PubMed Web of Science ®Google Scholar
• Wu Z, Wang YM, Dai Y, Chen LA. POLE2 Serves as a Prognostic Biomarker and Is Associated with Immune Infiltration in Squamous Cell Lung Cancer. Med Sci Monit. 2020;26:e921430. doi:10.12659/MSM.921430.
   Google Scholar
• Yeganeh PN, Richardson C, Bahrani-Mostafavi Z, Tait DL, Mostafavi MT. Dysregulation of AKT3 along with a small panel of mRNAs stratifies high-grade serous ovarian cancer from both normal epithelia and benign tumor tissues. Genes Cancer. 2017;8(11–12):784–798. doi:10.18632/genesandcancer.164
   PubMedGoogle Scholar
• Xia W, Mao W, Chen R, et al. Epidermal growth factor receptor mutations in resectable non-small cell lung cancer patients and their potential role in the immune landscape. Med Sci Monit. 2019;25:8764–8776. doi:10.12659/MSM.920042
   PubMed Web of Science ®Google Scholar
• Antomarchi J, Ambrosetti D, Cohen C, et al. Immunosuppressive tumor microenvironment status and histological grading of endometrial carcinoma. Cancer Microenviron. 2019;12(2–3):169–179. doi:10.1007/s12307-019-00225-1
   PubMed Web of Science ®Google Scholar